ArticleInternational journal of oncology2014

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer.

Allen Cohn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.